<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="AZTREONAM" rxcui="1272">
<ATC code="J01DF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the valproic acid, with risk of overdose. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of serious cutaneous reactions (Lyell&#39;s syndorme). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<CLASS name="PENEMS" code="J01DH" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="RUFINAMIDE" rxcui="69036">
<ATC code="N03AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="38404" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hyperammonemia with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE (AZT)" rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="ZONISAMIDE " rxcui="">
<ATC code="N03AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
